Braveheart Bio (BRVE) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trevi Therapeutics is the larger company by market cap ($1.89 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | TRVI |
|---|---|---|
| Share price | $20.13 | $13.27 |
| Market cap | $1.81B | $1.89B |
| 1-day change | +5.46% | +3.43% |
| YTD return | — | +2.44% |
| 1-year return | — | +30.60% |
| 5-year return | — | +894.19% |
| EPS (TTM) | $-6.08 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-42.76M |
| 52-week high | $32.00 | $20.22 |
| 52-week low | $17.86 | $9.28 |
| Distance from 52-week high | -37.09% | -34.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +124.79% | +112.44% |
| Average volume | 558.38K | 2.03M |
| Shares outstanding | 90.04M | 142.48M |
| Employees | 49 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
BRVE vs TRVI FAQ
Which is bigger, Braveheart Bio or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.89B compared with $1.81B for Braveheart Bio (BRVE).
Are Braveheart Bio and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.